• CRCL/CLB Seminar

The next CRCL/CLB seminar will take place Friday the 13th of September at 11.30am in the ONCORA meeting room (Centre Léon Bérard, 2nd floor).
We are pleased to welcome Nicolas Manel (Activation of innate immune sensors by viruses and self: DNA's identity crisis?). His talk will focus on Activation of innate immune sensors by viruses and self: DNA's identity crisis?”.


  • 4th International Symposium of the CRCL

The Cancer Research Center of Lyon (CRCL) is pleased to announce that its 
4th International Cancer Symposium / Cancer Research Center of Lyon will take place from the 2nd to the 4th of October in the Convention Center of Lyon, France.

This edition should not fall short of its predecessors, since top-ranking internationally renowned researchers, including one of the 2009 Nobel Prize winners in Chemistry, Pr. Ada Yonath, as well as F de Sauvage, JE Visvader, RA Weinberg, and SW Lowe, have already confirmed their attendance. Through the highly diversified presentations of these excellent researchers, the meeting will address crucial issues from both a cognitive and a clinical application standpoint.

Registration and abstract submission on


  • 18th Symposium on Purine and Pyrimidine Metabolism in Man

The 18th Symposium on Purine and Pyrimidine Metabolism in Man will be held in Lyon from 12-14 June 2019 at the International Agency for Research on Cancer.
Registration and abstract submission is open. 
More information on the website :


Co-organized by researchers at Lyon Cancer Research Center (CRCL), the Institute of Nanotechnology of Lyon (INL) and the Institute of Light Matter (ILM), this workshop aims at promoting exchanges and collaborations between physicists and biologists to bring out new concepts in understanding the mechanisms of cancer and in the development of future targeted therapies.

Abstract sumission and registration deadline : February, 15th
More information :

  • 2nd Innate Sensors community (InnaSCo) symposium

The 2nd Innate Sensors community (InnaSCo) symposium will be held in Lyon, France 15th-16th May 2019.

By attending you will have the opportunity to discuss your work and hear talks given by excellent scientists working in the field of Innate immune sensing and disease. Renowed scientists, including as a keynote speaker Nicolas Manel from the Curie Institute have accepted to give invited lectures for this second symposium. Several slots for short talks are available and we encourage everyone including students and post-doctoral fellows to submit an abstract.

Selection of talks and posters will be based on abstract submission. In addition, prizes for the best talk and poster will be awarded.


Deadline for registration and abstract submission 15th March 2019.

Registration is free but compulsory and places are limited:



  • LKB1 specifies neural crest cell fates through pyruvate-alanine cycling

Résultat de recherche d'images pour 'science advances' Metabolic Processes underlying the development of the neural crest, an embryonic population of multipotent migratory cells, are poorly understood. Here, we report that conditional ablation of the Lkb1 tumor suppressor kinase in mouse neural crest stem cells led to intestinal pseudo-obstruction and hind limb paralysis. This phenotype originated from a postnatal degeneration of the enteric nervous ganglia and from a defective differentiation of Schwann cells. Metabolomic profiling revealed that pyruvate-alanine conversion is enhanced in the absence of Lkb1. Mechanistically, inhibition of alanine transaminases restored glial differentiation in an mTOR-dependent manner, while increased alanine level directly inhibited the glial commitment of neural crest cells. Treatment with the metabolic modulator AICAR suppressed mTOR signaling and prevented Schwann cell and enteric defects of Lkb1 mutant mice. These data uncover a link between pyruvate-alanine cycling and the specification of glial cell fate with potential implications in the understanding of the molecular pathogenesis of neural crest diseases.
DOI : 10.1126/sciadv.aau5106

  • The Proto-oncogene c-Kit Inhibits Tumor Growth by Behaving as a Dependence Receptor

c-Kit is a classic proto-oncogene either mutated or upregulated in cancer cells, and this leads to its constitutive kinase activation and, thus, to uncontrolled proliferation. Although the pro-oncogenic role of c-Kit is of no doubt, some observations do not fit well with c-Kit solely as a tumor-promoting moiety. We show here that c-Kit actively triggers cell death in various cancer cell lines unless engaged by its ligand stem cell factor (SCF). This pro-death activity is enhanced when the kinase activation of c-Kit is silenced and is due to c-Kit intracellular cleavage by caspase-like protease at D816. Moreover, in vivo, overexpression of a c-Kit kinase-dead mutant inhibits tumor growth, and this intrinsic c-Kit tumor-suppressive activity is dependent on the D816 cleavage. Thus, c-Kit acts both as a proto-oncogene via its kinase activity and as a tumor suppressor via its dependence receptor activity.

  • Notch Signaling in the Tumor Microenvironment

The Notch signaling pathway regulates many aspects of cancer biology. Most attention has been given to its role in the transformed cell. However, it is now clear that cancer progression and metastasis depend on the bidirectional interactions between cancer cells and their environment, forming the tumor microenvironment (TME). These interactions are mediated and constantly evolve through paracrine and juxtacrine signaling. In this review, we discuss how Notch signaling takes an important part in regulating the crosstalk between the different compartments of the TME. We also address the consequences of the Notch-TME involvement from a therapeutic perspective.


  • August 2019 - Terchnician / Research Assistant position

The "Cell-death and childhood cancer" team offers a technician/research assistant position.
Available for highly motivated fellow interested in organoid technology approaches to develop innovative pediatric cancer models. Successful candidates will also be involved in lab organization and continuous improvement.
More information

  • August 2019 - postdoctoral position in bioinformatics

The "cell-death and chilhood cancer" team offers a 1-year contract for a postdoctoral position in bioinformatics applied to Next Generation Sequencing and Illumina technology.
More information

  • August 2019 - Postdoctoral position

The "cell-death and chilhood cancer team" offers a postdoctoral position.
Available for highly motivated post-doctoral fellow interested in conducting interdisciplinary research using in-vitro and in-silico approaches to develop innovative neuroblastoma models and use them to better understand the mechanisms of resistance to treatment in these pathologies.
More information

  • June 2019 - Engineer in bioinformatics

The group "Biology of Rare Sarcomas" (Dir. Franck Tirode) offer an 18-months position for an engineer in the field of bioinformatics applied to Next Generation Sequencing. 
Application deadline : August, 16th 
More information

  • Mai 2019 - Assistant Ingénieur ou Ingénieur d'Etude en immuno-oncologie

L’AI/IE participera à la conception, la réalisation mais aussi au suivi d’expériences réalisées dans le cadre de projets de recherche en immuno-oncologie développés dans le groupe du Dr Nathalie Bendriss-Vermare (CRCN INSERM, HDR) au sein de l’équipe dirigée par le Dr Christophe Caux au Centre de Recherche en Cancérologie de Lyon (CRCL).
Plus d'information

  • March 2019 - Postdoctoral fellow in bioinformatics

The group "Genetics, Epigenetics and biology of sarcomas" (Dir. Franck Tirode) is looking for a post-doc in bioinformatics (18 months). The project aims at identifying the molecular alterations and defining the precise tumor subtype of a large series of “still unclassified” sarcomas using multidimensional and integrative data analysis approaches.
More information

  • Mars 2019 - Ingénieur de recherche
La plateforme « Innovation en Immunomonitoring et Immunothérapie » (PI3) (PI : C Ménétrier-Caux) implantée sur le site du Centre Léon Bérard, recrute un ingénieur de recherche pour superviser l’activité sur le plan technologique et organisationnel.

Plus d'information

  • Mars 2019 - Ingénieur d'étude

Dans le cadre d’un projet de recherche, en partenariat avec un grand groupe pharmaceutique, portant sur les sous populations de lymphocytes T régulateurs dans les cancers du sein et l’identification de nouvelles cibles, l’équipe « Ciblage thérapeutique des cellules tumorales et de leur stroma immunitaire» du CRCL, dirigée par le Dr C Caux, recherche un ingénieur d'étude.
Plus d'information

Copyright 2011. CRCL